|
|
Peyronies
Disease
Peyronie's
disease, a condition of uncertain cause, is characterized
by a plaque, or hard lump, that forms on the penis.
The plaque develops on the upper or lower side of
the penis in layers containing erectile tissue. It
begins as a localized inflammation and can develop
into a hardened scar.
|
|
|
 |
 |
|
Cases
of Peyronie's disease range from mild to severe. Symptoms
may develop slowly or appear overnight. In severe cases, the
hardened plaque reduces flexibility, causing pain and
forcing the penis to bend or arc during erection. In many
cases, the pain decreases over time, but the bend in the penis
may remain a problem, making sexual intercourse difficult.
The sexual problems that result can disrupt a couple's physical
and emotional relationship and lead to lowered self-esteem
in the man. In a small percentage of patients with the milder
form of the disease, inflammation may resolve without causing
significant pain or permanent bending.
The plaque
itself is benign, or noncancerous. A plaque on the
top of the shaft (most common) causes the penis to bend upward;
a plaque on the underside causes it to bend downward. In some
cases, the plaque develops on both top and bottom, leading
to indentation and shortening of the penis. At times, pain,
bending, and emotional distress prohibit sexual intercourse.
One study
found Peyronie's disease occurring in 1 percent of
men. Although the disease occurs mostly in middle-aged men,
younger and older men can acquire it. About 30 percent of
people with Peyronie's disease develop fibrosis (hardened
cells) in other elastic tissues of the body, such as on the
hand or foot. A common example is a condition known as Dupuytren's
contracture of the hand. In some cases, men who are related
by blood tend to develop Peyronie's disease, which suggests
that familial factors might make a man vulnerable to the disease.
Men with
Peyronie's disease usually seek medical attention because
of painful erections and difficulty with intercourse. Since
the cause of the disease and its development are not well
understood, doctors treat the disease empirically; that is,
they prescribe and continue methods that seem to help. The
goal of therapy is to keep the Peyronie's patient sexually
active. Providing education about the disease and its
course often is all that is required. No strong evidence shows
that any treatment other than surgery is effective. Experts
usually recommend surgery only in long-term cases in which
the disease is stabilized and the deformity prevents intercourse.
A French
surgeon, François de la Peyronie, first described Peyronie's
disease in 1743. The problem was noted in print as early as
1687. Early writers classified it as a form of impotence,
now called erectile dysfunction (ED). Peyronie's disease can
be associated with ED; however, experts now recognize ED
as only one factor associated with the disease--a factor that
is not always present.
|

 |
Course
of the Disease
Many researchers
believe the plaque of Peyronie's disease develops following
trauma (hitting or bending) that causes localized bleeding
inside the penis. Two chambers known as the corpora cavernosa
run the length of the penis. The inner-surface membrane of
the chambers is a sheath of elastic fibers. A connecting tissue,
called a septum, runs along the center of each chamber and
attaches at the top and bottom.
If the
penis is abnormally bumped or bent, an area where the
septum attaches to the elastic fibers may stretch beyond a
limit, injuring the lining of the erectile chamber and, for
example, rupturing small blood vessels. As a result of aging,
diminished elasticity near the point of attachment of the
septum might increase the chances of injury.
The damaged
area might heal slowly or abnormally for two reasons:
repeated trauma and a minimal amount of blood flow in the
sheath-like fibers. In cases that heal within about a year,
the plaque does not advance beyond an initial inflammatory
phase. In cases that persist for years, the plaque undergoes
fibrosis, or formation of tough fibrous tissue, and even calcification,
or formation of calcium deposits.
While
trauma might explain acute cases of Peyronie's disease,
it does not explain why most cases develop slowly and with
no apparent traumatic event. It also does not explain why
some cases disappear quickly, and why similar conditions such
as Dupuytren's contracture do not seem to result from severe
trauma.
Some researchers
theorize that Peyronie's disease may be an autoimmune
disorder.
A number
of drugs list Peyronie's disease as a possible side effect.
Most of these drugs belong to a class of blood pressure and
heart medications called beta blockers. One beta blocker is
an eye drop preparation used to treat glaucoma. Other drugs
that may cause Peyronie's disease are interferon, used to
treat multiple sclerosis, and phenytoin, an anti-seizure medicine.
The chances of developing Peyronie's disease from any of these
medicines are very low. Patients should check with their doctor
before discontinuing any prescribed drug.
|

Peyronies
Treatment
Because
the course of Peyronie's disease is different in each
patient and because some patients experience improvement without
treatment, medical experts suggest waiting 1 to 2 years or
longer before attempting to correct it surgically. During
that wait, patients often are willing to undergo treatments
whose effectiveness has not been proven.
Some researchers
have given men with Peyronie's disease vitamin E orally
in small-scale studies and have reported improvements. Yet,
no controlled studies have established the effectiveness of
vitamin E therapy. Similar inconclusive success has been attributed
to oral application of para-aminobenzoate, a substance belonging
to the family of B-complex molecules.
Researchers
have injected chemical agents such as verapamil, collagenase,
steroids, and calcium channel blockers directly into the plaques.
These interventions are still considered unproven because
studies have included low numbers of patients and have lacked
adequate control groups. Steroids, such as cortisone,
have produced unwanted side effects, such as the atrophy or
death of healthy tissues. Another intervention involves iontophoresis,
the use of a painless current of electricity to deliver verapamil
or some other agent under the skin to the plaque.
Radiation
therapy, in which high-energy rays are aimed at the plaque,
has also been used. Like some of the chemical treatments,
radiation appears to reduce pain, but it has no effect at
all on the plaque itself and can cause unwelcome side effects.
Although the variety of agents and methods used points to
the lack of a proven treatment, new insights into the wound
healing process may yield more effective therapies in the
near future.
Peyronie's
disease has been treated with some success by surgery.
The two most common surgical methods are removal or expansion
of the plaque followed by placement of a patch of skin or
artificial material, and removal or pinching of tissue from
the side of the penis opposite the plaque, which cancels out
the bending effect. The first method can involve partial
loss of erectile function, especially rigidity. The second
method, known as the Nesbit procedure, causes a shortening
of the erect penis.
Some men
choose to receive an implanted device that increases rigidity
of the penis. In some cases, an implant alone will straighten
the penis adequately. In other cases, implantation is combined
with a technique of incisions and grafting or plication (pinching
or folding the skin) if the implant alone does not straighten
the penis.
Most types
of surgery produce positive results. But because complications
can occur, and because many of the phenomena associated with
Peyronie's disease (for example, shortening of the penis)
are not corrected by surgery, most doctors prefer to perform
surgery only on the small number of men with curvature so
severe that it prevents sexual intercourse.
|
|